BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  TwoStep Therapeutics to Present at the 2025 SITC Annual Meeting

  November 10, 2025

   · 

  1 min read
• Press Releases

  Klotho Neurosciences Wins the 2025 BioTech Breakthrough ‘Cell Therapy Innovation of the Year’ Award

  November 10, 2025

   · 

  2 min read
• Press Releases

  Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

  November 10, 2025

   · 

  8 min read
• Press Releases

  Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test

  November 10, 2025

   · 

  8 min read
• Press Releases

  Fulgent Reports Third Quarter 2025 Financial Results

  November 10, 2025

   · 

  15 min read
• Press Releases

  Gilead Provides Update on Phase 3 ASCENT-07 Study

  November 10, 2025

   · 

  16 min read
• Press Releases

  Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

  November 10, 2025

   · 

  10 min read
• Press Releases

  Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

  November 10, 2025

   · 

  7 min read
• Press Releases

  Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers

  November 10, 2025

   · 

  8 min read
• Press Releases

  Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025

  November 10, 2025

   · 

  6 min read